Avanos Medical (AVNS)
(Delayed Data from NYSE)
$24.00 USD
+0.46 (1.95%)
Updated Sep 13, 2024 04:00 PM ET
After-Market: $23.99 -0.01 (-0.04%) 5:38 PM ET
2-Buy of 5 2
B Value D Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$24.00 USD
+0.46 (1.95%)
Updated Sep 13, 2024 04:00 PM ET
After-Market: $23.99 -0.01 (-0.04%) 5:38 PM ET
2-Buy of 5 2
B Value D Growth B Momentum B VGM
Zacks News
Avanos Medical (AVNS) Q4 Earnings, Revenues Top Estimates
by Zacks Equity Research
Avanos Medical's (AVNS) fourth-quarter 2021 results gain from strength in the chronic care segment.
Avanos Medical (AVNS) Beats Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Avanos Medical (AVNS) delivered earnings and revenue surprises of 15% and 1.63%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Avanos Medical (AVNS) Earnings Expected to Grow: What to Know Ahead of Q4 Release
by Zacks Equity Research
Avanos Medical (AVNS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Strong Sell Stocks for January 24th
by Zacks Equity Research
AGNC, AVNS, and SQ have been added to the Zacks Rank #5 (Strong Sell) List on January 24, 2022
Intuitive Surgical, Inc. (ISRG) Beats Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Intuitive Surgical, Inc. (ISRG) delivered earnings and revenue surprises of 1.56% and 0.76%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
New Strong Sell Stocks for January 19th
by Zacks Equity Research
ONEM, ALXO, and AVNS have been added to the Zacks Rank #5 (Strong Sell) List on January 19, 2022
Avanos Medical (AVNS) Set to Acquire OrthogenRx for $160M
by Zacks Equity Research
Avanos Medical's (AVNS) deal to acquire OrthogenRx is likely to boost the company's chronic pain portfolio.
Avanos Medical's (AVNS) App to Support Pain Management Process
by Zacks Equity Research
Avanos Medical's (AVNS) new solution to help healthcare providers with respect to patients' overall pain management process.
Avanos Medical (AVNS) Down 17.6% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Avanos Medical (AVNS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Avanos Medical (AVNS) Q3 Earnings Lag Estimates, Revenues Top
by Zacks Equity Research
Avanos Medical's (AVNS) third-quarter 2021 results gains from strength in the Pain Management segment.
Avanos Medical (AVNS) Q3 Earnings Lag Estimates
by Zacks Equity Research
Avanos Medical (AVNS) delivered earnings and revenue surprises of -7.41% and 0.11%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Avanos Medical (AVNS) to Report Q3 Results: Wall Street Expects Earnings Growth
by Zacks Equity Research
Avanos Medical (AVNS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Is Avanos Medical (AVNS) Down 2.2% Since Last Earnings Report?
by Zacks Equity Research
Avanos Medical (AVNS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Avanos Medical (AVNS) Q2 Earnings Lag Estimates, Revenues Top
by Zacks Equity Research
Avanos Medical's (AVNS) second-quarter 2021 results gains from strength in Pain Management segment.
What's in Store for Senseonics Holdings' (SENS) Q2 Earnings?
by Zacks Equity Research
Senseonics Holdings' (SENS) second-quarter results are likely to gain from higher sales outside the United States.
DENTSPLY SIRONA (XRAY) to Post Q2 Earnings: What's in Store?
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) second-quarter results are likely to reflect strong segmental performance.
Avanos Medical (AVNS) Q2 Earnings Miss Estimates
by Zacks Equity Research
Avanos Medical (AVNS) delivered earnings and revenue surprises of -8.70% and 2.36%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Cardinal Health (CAH) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
Cardinal Health's (CAH) fiscal fourth-quarter results are likely to reflect solid performance in Pharmaceutical segment.
McKesson (MCK) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
McKesson's (MCK) fiscal first-quarter results are likely to reflect solid show by U.S. Pharmaceutical and Specialty Solutions segment.
AmerisourceBergen (ABC) to Post Q3 Earnings: What's in Store?
by Zacks Equity Research
AmerisourceBergen's (ABC) fiscal third-quarter results are likely to reflect solid performance at Pharmaceutical Distribution and Other units.
Avanos Medical (AVNS) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Avanos Medical (AVNS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Avanos Medical (AVNS) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Avanos Medical (AVNS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Cerner (CERN) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Cerner's (CERN) second-quarter results are likely to reflect gains from strategic deals.
What's in Store for West Pharmaceutical's (WST) Q2 Earnings?
by Zacks Equity Research
West Pharmaceutical's (WST) second-quarter results are likely to reflect strength in the Proprietary Products business.
DexCom (DXCM) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
DexCom's (DXCM) second-quarter results are likely to reflect rising global awareness of its real-time CGM.